biologic

Berinert

C1 Esterase Inhibitor (Human)

Loss of exclusivityOctober 2021projected — 12-year biologic exclusivity estimate
CompanyCSL BehringSee this company's full patent-cliff portfolio

Drug detail

Brand nameBerinert
Active ingredientC1 Esterase Inhibitor (Human)
Strength500U
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2009
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Berinert patent cliff — loss of exclusivity October 2021 | CliffBio